| Institution | Analyst | Contact | Recomendation | Target Price | Last Revision |
|---|---|---|---|---|---|
| Itaú | Marcelo Sá | marcelo.a-sa@itaubba.com | Outperform | R$ 50.10 | 05/08/2024 |
| BTG Pactual | Antonio Junqueira | antonio.junqueira@btgpactual.com | Buy | R$ 48.00 | 10/30/2024 |
| XP Investimentos | Vladimir Pinto | vladimir.pinto@xpi.com.br | Buy | R$ 46,00 | 08/27/2024 |
| Safra | Carolina Carneiro | carolina.carneiro@safra.com.br | Outperform | R$ 44.60 | 08/21/2024 |
| UBS | Giuliano Ajeje | giuliano.ajeje@ubs.com | Buy | R$ 44.00 | 11/18/2024 |
| Scotiabank | Renato Pinto | renato.pinto@scotiabank.com | Outperform | R$ 44,00 | 09/12/2024 |
| Santander | André Sampaio | ansampaio@santander.com.br | Buy | R$ 43.67 | 02/08/2024 |
| Bradesco | Francisco Navarrete | francisco.navarrete@bradescobbi.com.br | Outperform | R$ 43.00 | 06/28/2024 |
| Goldman Sachs | Bruno Amorim | bruno.amorim@gs.com | Buy | R$ 42.90 | 13/11/2024 |
| JP Morgan | Victor Burke | victor.burke@jpmchase.com | Hold | R$ 42.00 | 08/21/2024 |
| Itaú | Marcelo Sá | marcelo.a-sa@itaubba.com | Outperfom | R$ 42.00 | 12/19/2023 |
| BofA Merrill Lynch | Arthur Pereira | arthur.pereira@bofa.com | Buy | R$ 41,00 | 08/13/2024 |
| Morgan Stanley | Fernando Amaral | Fernando.Amaral@morganstanley.com | Overweight | R$ 37.77 | 11/13/2024 |
| HSBC | Lilyanna Yang | lilyanna.yang@us.hsbc.com | Hold | R$ 38.00 | 07/15/2024 |
| Average | R$ 43.46 | ||||
| Minimal | R$ 38.00 | ||||
| Maximum | R$ 50.10 |
Equatorial is covered by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Equatorial´s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Equatorial or its management. Equatorial does not, by its reference above or distribution, imply its endorsement of or concurrence with such information, conclusions or recommendations. Equatorial does not warrant that the above list of analysts is complete nor updated, and the information herein provided are subject to the authorization of the analysts.